Home InMed Pharmaceuticals Inc. (OTCMKTS: IMLFF) Sets Up a Bull Flag in Explosive Canadian Pot Space

InMed Pharmaceuticals Inc. (OTCMKTS: IMLFF) Sets Up a Bull Flag in Explosive Canadian Pot Space

New Trade Alert:  InMed Pharmaceuticals Inc. (OTCMKTS: IMLFF)

As you know, one theme we see as extremely powerful right now is the Canadian cannabis space. In the aftermath of the US elections (when 8 out of 9 states with ballot propositions on marijuana passed their measures to push pot into more legal ground), the next anticipatory run for pot stocks will be Canada.


Because Justin Trudeau, the Prime Minister of Canada, got into office on a ticket that included a stated, explicit promise to make marijuana legal, on a full recreational basis, for all of Canada during 2017. That means, the big catalyst for Canadian pot stocks is still just ahead.

New research is also out showing that a massive jump in demand for medical cannabis in Canada is just around the corner that could bring thousands of pounds of demand onto the legal market over the near term.

We believe this will light a fire under the whole space.

Symbol:  IMLFF

Company:  InMed Pharmaceuticals Inc.

Quote:  http://finance.yahoo.com/q?s=IMLFF

Latest News:  http://finance.yahoo.com/q/h?s=IMLFF+Headlines

Company Website:  http://www.inmedpharma.com

InMed Pharmaceuticals Inc. (OTCMKTS: IMLFF) is a pre-clinical stage biopharmaceutical company that engages in the research and development of novel and cannabinoid-based therapies in Canada.

The company’s products under pre-clinical development stage include INM-750 for the treatment of epidermolysis bullosa; and INM-085 for the treatment of glaucoma. It is also developing various drugs for diseases, such as ocular, pain and inflammation, dermatology, central nervous system, metabolic, and respiratory.

IMLFF also just announced progress on its R&D program in the use of cannabinoids for the treatment of chronic obstructive pulmonary disease (COPD).

Note, the global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach a value of $15.6 billion by 2019 according to GBI Research.

In June, 2015, IMLFF initiated its COPD program using its bioinformatics analysis tool to identify the targets and potential active compounds that can be useful for the treatment of COPD.

“Subsequently, with in vitro assays using human lung fibroblasts (HFL-1 cell line), InMed has demonstrated that certain cannabinoid compounds are capable of affecting a specific protein in the biochemical pathway relevant to healing and fibrosis in the lung.” (See Full Press Release Here).

According to a recent Bloomberg article, Canada’s push to legalize marijuana could be a “game changer” for the recreational pot industry with the potential to reach C$6 billion ($4.5 billion) in sales by 2021.

A massive black market for marijuana exists in Canada that Canaccord Genuity analysts believe, if brought into legal channels, might bring about sales of 400K kg, or nearly 900K lbs, of cannabis in year one.

If legalization occurs along expected timelines there will be about 3.8 million legal recreational users of marijuana across Canada by 2021, according to the note.

Demand for medical cannabis is growing at a significant pace and by 2021, combined annual demand for medical and recreational cannabis will be about 575,000 kilograms, the Canaccord report said.

The chart for IMLFF is a thing of beauty at the moment as well. This is a near-perfect Bull Flag pattern with huge upside potential on its next breakout.


IMLFF (InMed Pharmaceuticals Inc. ) a company that InMed Pharmaceuticals, a pre-clinical stage biopharmaceutical company, engages in the research and development of novel and cannabinoid-based therapies in Canada.

IMLFF’s products under pre-clinical development stage include INM-750 for the treatment of epidermolysis bullosa; and INM-085 for the treatment of glaucoma.

IMLFF is also developing various drugs for diseases, such as ocular, pain and inflammation, dermatology, central nervous system, metabolic, and respiratory.

IMLFF was formerly known as Cannabis Technologies and changed its name to InMed Pharmaceuticals in October 2014. InMed Pharmaceuticals was incorporated in 1981 and is based in Vancouver, Canada.

What You Need To Know: 

  • IMLFF is positioned to benefit from a massive surge in medical cannabis in Canada over the coming year, according to several research reports.
  • IMLFF is moving into the $15B COPD space according to very recent press.
  • IMLFF is coming off an RSI trough under 40, pointing to a massively oversold stock now heading back the other way.
  • IMLFF just recorded a MACD Bullish reversal, suggesting a technical change in trend.
  • IMLFF is in a near-perfect Bull Flag pattern after breaking higher this Fall.



IMLFF may be poised for something special. The big picture looks like this: A new trend up got started in the Fall, and the initial explosive move in that trend has been consolidating like a coiling spring. Now it may be time for the spring to ‘pop’ and the move higher to resume.

If things play out here in terms of the research and forward calendar of catalysts, this could unleash a massive move higher from present levels in IMLFF.

Don’t miss the boat!


Trade Green !


Disclaimer: Past performance is not an indicator of future returns. We are not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities.Never make investment decisions based on anything Journal Transcript says. This message is meant for informational and educational purposes only and does not provide investment advice. The report/release/profile/articles is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.  The paying party may own shares and may liquidate them during the promotional period. Please note have been compensated 2500 USD for distribution of this email on IMLFF by an unaffiliated 3rd party Cream Consulting LLC.

PLEASE NOTE WELL: JournalTranscript.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. JOURNALTRANSCRIPT.COMWILL NEVER ACCEPT FREE OR RESTRICTED TRADING SHARES IN ANY COMPANIES MENTIONED at JOURNALTRANSCRIPT.COM&/OR ANY OF OUR SOCIAL NETWORKING AND EMAIL ADVERTISING PLATFORMS.

You are reading this newsletter because you have subscribed via our Opt-In Signup form on our Website. If you have been subscribed by mistake, you may unsubscribe HERE. Our website and newsletter are for Entertainment purposes only.  This newsletter is NOT a source of unbiased information.  Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.

We encourage all to read the SEC INVESTOR ALERT before reading our Newsletter.

Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold JournalTranscript.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. JournalTranscript.com sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by JournalTranscript.com or an offer or solicitation to buy or sell any security.

We expect to receive  future compensation.  JournalTranscript.com does not own any shares or positions on this profile. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. JournalTranscript.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and JournalTranscript.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further, JournalTranscript.com has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news & press releases, changes in corporate structure, or changes in share structure.

None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead JournalTranscript.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. JournalTranscript.com is compliant with the Can Spam Act of 2003. JournalTranscript.com does not offer such advice or analysis, and JournalTranscript.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.

In preparing this publication, JournalTranscript.com has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, JournalTranscript.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. JournalTranscript.com is not responsible for any claims made by the companies advertised herein, nor is JournalTranscript.com responsible for any other promotional firm, its program or its structure. We have not been compensated for distribution of this email.